Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373087
Status:
COMPLETED
Last Update Posted:
2010-04-29
First Post:
2006-09-06
Brief Title:
COMT Polymorphism and Entacapone Efficacy
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COMT
Brief Summary:
Entacapone is an antiparkinsonian drug which block L-dopa metabolism inhibiting the C-O-methyltransferase COMT enzyme There is an individual variability of the COMT activity determined by a genetic polymorphism The aim of this study is to investigate whether the genetic variability influences entacapone efficacy in Parkinsons disease
Detailed Description:
COMT protein is dependent of a single autosomal locus with two co-dominant alleles with a high activity allele H and a low activity allele L form of the enzyme L and H allele frequency in the Caucasian population is around 50 This is a monocentric randomized blinded cross-over study comparing acute challenge of L-dopa placebo versus L-dopa 200 mg entacapone in Parkinsons disease patients with HH and LL genotypes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None